Profile data is unavailable for this security.
About the company
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.
- Revenue in USD (TTM)0.00
- Net income in USD-119.58m
- Incorporated2018
- Employees49.00
- LocationInstil Bio Inc3963 Maple Avenue, Suite 350DALLAS 75219United StatesUSA
- Phone+1 (972) 499-3350
- Fax+1 (302) 531-3150
- Websitehttps://instilbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tenaya Therapeutics Inc | 0.00 | -117.23m | 203.60m | 140.00 | -- | 1.81 | -- | -- | -1.44 | -1.44 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -70.20 | -- | -78.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -25.91m | 203.73m | 10.00 | -- | 2.54 | -- | -- | -0.2064 | -0.2064 | 0.00 | 0.6374 | 0.00 | -- | -- | 0.00 | -26.68 | -29.97 | -28.00 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| CAMP4 Therapeutics Corp | 350.00k | -49.71m | 205.00m | 58.00 | -- | -- | -- | 585.71 | -2.55 | -2.55 | 0.0179 | 0.7707 | -- | -- | -- | 5,468.75 | -- | -- | -- | -- | -- | -- | -14,203.71 | -- | -- | -- | 0.0221 | -- | -- | -- | -11.54 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -19.37m | 208.86m | 13.00 | -- | 18.67 | -- | -- | -1.16 | -1.16 | 0.00 | 0.5789 | 0.00 | -- | -- | 0.00 | -97.93 | -- | -140.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Adaptimmune Therapeutics PLC - ADR | 141.46m | -72.50m | 210.76m | 449.00 | -- | 2.19 | -- | 1.49 | -0.3452 | -0.3452 | 0.5922 | 0.3765 | 0.4256 | -- | 53.33 | 315,053.40 | -21.81 | -41.19 | -28.63 | -48.21 | -- | -- | -51.25 | -714.26 | -- | -- | 0.2058 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| TuHURA Biosciences Inc | 0.00 | -8.50m | 211.83m | 1.00 | -- | -- | -- | -- | -75.24 | -75.24 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -163.44 | -224.08 | -343.80 | -346.74 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.40 | -- | -- | -- |
| Benitec Biopharma Inc | 0.00 | -22.37m | 212.81m | 16.00 | -- | 2.29 | -- | -- | -7.63 | -7.63 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -76.76 | -103.21 | -91.06 | -123.13 | -- | 152.10 | -- | -26,432.69 | -- | -- | 0.00 | -- | -100.00 | -- | -14.35 | -- | -15.35 | -- |
| Cabaletta Bio Inc | 0.00 | -89.98m | 217.87m | 136.00 | -- | 1.08 | -- | -- | -1.92 | -1.92 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -44.76 | -33.76 | -47.90 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Instil Bio Inc | 0.00 | -119.58m | 218.73m | 49.00 | -- | 1.12 | -- | -- | -18.39 | -18.39 | 0.00 | 29.98 | 0.00 | -- | -- | 0.00 | -34.04 | -- | -35.48 | -- | -- | -- | -- | -- | -- | -- | 0.2958 | -- | -- | -- | 30.06 | -- | -- | -- |
| XBiotech Inc | 0.00 | -35.01m | 222.38m | 94.00 | -- | 1.13 | -- | -- | -1.15 | -1.15 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -15.53 | 31.88 | -16.32 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0484 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -34.97m | 226.42m | 19.00 | -- | 1.70 | -- | -- | -5.82 | -5.82 | 0.00 | 10.92 | 0.00 | -- | -- | 0.00 | -35.74 | -86.84 | -45.03 | -130.46 | -- | -- | -- | -769.76 | -- | -29.78 | 0.0794 | -- | -- | -- | -5.33 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 81.63m | -20.23m | 227.14m | 76.00 | -- | 0.8276 | -- | 2.78 | -0.3507 | -0.3507 | 1.31 | 4.40 | 0.2746 | -- | 29.13 | 1,074,079.00 | -6.81 | -50.55 | -7.14 | -55.91 | -- | -- | -24.79 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 230.32m | 145.00 | -- | 1.55 | -- | 3.20 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Amarin Corporation plc (ADR) | 241.02m | -39.35m | 230.35m | 275.00 | -- | 0.4334 | -- | 0.9557 | -0.0959 | -0.0959 | 0.5876 | 1.29 | 0.3032 | 0.4387 | 2.05 | 876,440.00 | -4.95 | -4.48 | -7.02 | -6.54 | 56.46 | 75.70 | -16.32 | -8.59 | 2.11 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Onkure Therapeutics Inc | 0.00 | -41.03m | 234.11m | 8.00 | -- | 0.7928 | -- | -- | -12.25 | -12.25 | 0.00 | 22.14 | 0.00 | -- | -- | 0.00 | -39.45 | -- | -42.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -44.32m | 235.98m | 25.00 | -- | 3.93 | -- | -- | -0.4412 | -0.4412 | 0.00 | 0.7815 | 0.00 | -- | -- | 0.00 | -53.78 | -47.39 | -58.89 | -54.41 | -- | -- | -- | -- | -- | -- | 0.001 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
Data as of Nov 12 2024. Currency figures normalised to Instil Bio Inc's reporting currency: US Dollar USD
28.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| CPMG, Inc.as of 30 Jun 2024 | 410.92k | 6.32% |
| Perceptive Advisors LLCas of 17 Sep 2024 | 345.55k | 5.31% |
| BML Capital Management LLCas of 30 Sep 2024 | 335.00k | 5.15% |
| Cable Car Capital LLCas of 30 Jun 2024 | 258.10k | 3.97% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 127.81k | 1.97% |
| Nantahala Capital Management LLCas of 30 Jun 2024 | 127.29k | 1.96% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 116.26k | 1.79% |
| Marshall Wace LLPas of 30 Jun 2024 | 60.63k | 0.93% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 41.54k | 0.64% |
| Geode Capital Management LLCas of 30 Jun 2024 | 36.39k | 0.56% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
